.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Queensland Health
Moodys
Mallinckrodt
Johnson and Johnson
Chubb
Julphar
McKinsey
Teva
Fish and Richardson

Generated: September 25, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Plasmid capable of expressing human growth hormone
Abstract:Described are methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.
Inventor(s): Goeddel; David V. (Burlingame, CA), Heyneker; Herbert L. (Burlingame, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Filing Date:Aug 26, 1981
Application Number:06/296,099
Claims:1. A replicable bacterial plasmid which, in a transformant bacterium, will express a gene for human growth hormone unaccompanied by the human growth hormone leader sequence or other extraneous protein bound thereto.

2. A plasmid according to claim 1 whose human growth hormone-encoding gene comprises in substantial proportion cDNA or a replication thereof.

3. A plasmid according to claim 2 which exhibits resistance to at least one antibiotic.

4. A plasmid according to claim 3 which lacks the tet promoter yet exhibits tetracycline resistance.

5. A plasmid according to claim 4 in which the human growth hormone-encoding gene is under the control of tandem lac promoters.

6. The plasmid pHGH107.

7. The plasmid pHGH107-1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Mallinckrodt
UBS
McKinsey
Farmers Insurance
Queensland Health
Teva
Covington
Boehringer Ingelheim
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot